These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23294785)

  • 1. No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study.
    Danne T; Forst T; Deinhard J; Rose L; Moennig E; Haupt A
    J Diabetes Sci Technol; 2012 Nov; 6(6):1392-7. PubMed ID: 23294785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preference for a new prefilled insulin pen compared with the original pen.
    Garg S; Bailey T; DeLuzio T; Pollom D
    Curr Med Res Opin; 2011 Dec; 27(12):2323-33. PubMed ID: 21988614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of the HumaPen Luxura HD pen: what is the role of 0.5-unit insulin dosing?
    Magnotti MA; Rayfield EJ
    J Diabetes Sci Technol; 2010 Mar; 4(2):357-8. PubMed ID: 20307397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
    Lind M; Polonsky W; Hirsch IB; Heise T; Bolinder J; Dahlqvist S; Schwarz E; Ólafsdóttir AF; Frid A; Wedel H; Ahlén E; Nyström T; Hellman J
    JAMA; 2017 Jan; 317(4):379-387. PubMed ID: 28118454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
    Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
    JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of "no effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study".
    Ampudia-Blasco FJ
    J Diabetes Sci Technol; 2012 Nov; 6(6):1398-400. PubMed ID: 23294786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes.
    Karges B; Schwandt A; Heidtmann B; Kordonouri O; Binder E; Schierloh U; Boettcher C; Kapellen T; Rosenbauer J; Holl RW
    JAMA; 2017 Oct; 318(14):1358-1366. PubMed ID: 29049584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novopen Echo® for the delivery of insulin: a comparison of usability, functionality and preference among pediatric subjects, their parents, and health care professionals.
    Olsen BS; Lilleøre SK; Korsholm CN; Kracht T
    J Diabetes Sci Technol; 2010 Nov; 4(6):1468-75. PubMed ID: 21129343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study.
    Bohannon N; Bergenstal R; Cuddihy R; Kruger D; List S; Massaro E; Molitch M; Raskin P; Remtema H; Strowig S; Whitehouse F; Brunelle RL; Dreon D; Tan M
    Diabetes Technol Ther; 2011 Oct; 13(10):1031-7. PubMed ID: 21732797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term metabolic effects of continuous subcutaneous insulin infusion therapy in type 1 diabetes.
    Cohen ND; Hong ES; Van Drie C; Balkau B; Shaw J
    Diabetes Technol Ther; 2013 Jul; 15(7):544-9. PubMed ID: 23617252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fear of hypoglycemia in type 1 diabetes managed by continuous subcutaneous insulin infusion: is it associated with poor glycemic control?
    Nixon R; Pickup JC
    Diabetes Technol Ther; 2011 Feb; 13(2):93-8. PubMed ID: 21284474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes.
    Seggelke SA; Hawkins RM; Gibbs J; Rasouli N; Wang CC; Draznin B
    Endocr Pract; 2014 Jun; 20(6):536-9. PubMed ID: 24326004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of Professional Continuous Glucose Monitoring in improving glycemic control among children with Type 1 Diabetes Mellitus: An Open-label Randomized Control Trial.
    Raviteja KV; Kumar R; Dayal D; Sachdeva N
    Sci Rep; 2019 Apr; 9(1):6120. PubMed ID: 30992480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes.
    Krzymień J; Kobli T; Nazar M
    Pol Arch Med Wewn; 2010 Nov; 120(11):444-50. PubMed ID: 21102380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
    Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
    Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes.
    Hirsch LJ; Gibney MA; Albanese J; Qu S; Kassler-Taub K; Klaff LJ; Bailey TS
    Curr Med Res Opin; 2010 Jun; 26(6):1531-41. PubMed ID: 20429832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.